猪细小病毒VP2蛋白在干酪乳杆菌表面的表达

将编码猪细小病毒主要免疫保护性抗原VP2基因插入干酪乳杆菌细胞表面表达载体pPG中,构建了重组表达载体pPG-VP2,将其电转化干酪乳杆菌Lactobacillus casei 393,获得了表达猪细小病毒VP2蛋白的重组干酪乳杆菌系统,经2%乳糖在MRS培养基中的诱导表达,SDS-PAGE检测表明,有约74kD蛋白得到了表达,表达蛋白的大小与理论值相符。Western-blot结果分析表明,表达的蛋白可被鼠源PPV抗血清所识别,间接免疫荧光实验结果表明,所表达的蛋白能够在干酪乳杆菌菌体表面检测到。     

重组家蚕病毒表达传染性法氏囊病病毒VP2蛋白

将传染性囊病病毒ＨＺ９６株主要宿主保护性抗原ＶＰ２的ｃＤＮＡ基因克隆到杆状病毒转移载体ｐＢａｃ－ＰＡＫ８中,获得重组转移载体ｐＢａｃＰＡＫ－ＶＰ２,载体ｐＢａｃＰＡＫ－ＶＰ２与修饰病毒Ｂｍ－ＢａｃＰＡＫ６线性化基因组ＤＮＡ共转染单层家蚕Ｂｏｍｂｙｘ ｍｏｒｉ（Ｂｍ）Ｎ细胞,经细胞内同源重组,筛选到重组病毒。ＥＬＩＳＡ和Ｗｅｓｔｅｒｎ免疫鲩迹结果表明,ＶＰ２在家蚕培养细胞和家蚕幼虫中均得到了表达。     

传染性法氏囊病病毒多聚蛋白基因在家蚕中的表达

将传染性法氏囊病病毒(IBDV)细胞致弱株(JD1株)的基因组A节段基因重组于家蚕杆状病毒转移载体pAcHLT-C中,获得的重组转移载体pAcHLT-C-A与线性化病毒Bm-BacPAK6 DNA共转染家蚕培养细胞,获得重组病毒BacPAK-A。DIG标记的DNA点杂交证实重组病毒基因组中含有A节段基因,重组病毒感染家蚕5龄幼虫进行表达, ELISA和Western blotting等结果表明多聚蛋白基因在蚕体内得到了表达,表达产物具有免疫反应性,表达量在感染后5～6 d达到最高。家蚕生物反应器表达IBDV多聚蛋白具有我国的资源优势,为今后研制低成本、实用化的IBDV基因工程疫苗打下基础。     

MDV-1 VP22增强鸡传染性法氏囊炎病毒VP2 DNA免疫作用

马立克氏病病毒（Marek’s disease virus,MDV）被膜成分中的VP22具有蛋白转导功能．将鸡传染性法氏囊炎病毒（infectious bursal disease virus,IBDV）VP2与MDV—VP22同时插入pcDNA3．1构建融合蛋白表达载体,在COS-1细胞中进行暂态表达．结果表明：VP22并不能促进VP2向周围未转染细胞转导,即VP22对VP2没有明显的蛋白转导作用,相反,VP2影响VP22在细胞内的正常定位．然而,通过小鼠股四头肌免疫注射PEI包裹的裸质粒DNA进行DNA免疫,以间接ELISA测定VP2抗体效价,FACS检测T细胞亚类．发现,虽然VP22没有明显促进VP2的体液免疫应答,但脾脏淋巴细胞分群结果表明,VP22-VP2融合蛋白表达载体免疫组和VP2质粒免疫组的CD3^＋T细胞数量显著高于eGFP-VP2组和对照组（P〈0．05）,融合蛋白表达载体免疫组小鼠CD8^＋／CD4^＋T细胞的比例与VP2质粒免疫组相比,明显增强（P〈0．05）,与对照组相比差异极显著（P〈0．01）．这表明VP22对VP2的特异性细胞免疫反应具有一定增强作用．     

鸡传染性法氏囊病病毒非结构蛋白基因的克隆、表达及多克隆抗体制备

利用RT-PCR技术从传染性法氏囊病病毒(IBDV)TL2004株感染鸡胚尿囊液中扩增到VP5基因,进而构建了T7启动子控制下的N端GST-Tag融合表达质粒pGEX-VP5。序列测定表明VP5基因全长438bp,编码一个由145个氨基酸组成的VP5蛋白。将pGEX-VP5转化大肠杆菌BL21,在IPTG的诱导下高效表达了GST-VP5融合蛋白(44kD)。通过包涵体纯化的方法,获得的较高纯度的融合蛋白,免疫新西兰兔,Western blot和ELISA分析表明,制备的融合蛋白抗血清效价在1∶12800以上,并具有良好的免疫反应特异性,为进一步研究VP5在IBDV复制与致病中的作用,以及研制IBDVVP5基因缺失疫苗打下了良好的基础。     

表面展示新城疫病毒部分F蛋白的重组干酪乳杆菌的构建及其免疫原性

本研究旨在构建重组干酪乳杆菌pLA-Newcastlediseasevirus (NDV)-F/Lactobacillus casei,获得表达产物,并探讨其免疫效果。利用PCR扩增携带部分主要抗原表位的NDV F基因,与穿梭质粒pLA连接转化至大肠杆菌BL21 (DE3)中,筛选阳性重组质粒,将其电转化至干酪乳杆菌中,构建重组干酪乳杆菌pLA-NDV-F/L. casei,应用PCR鉴定阳性菌株,Western blotting鉴定重组菌反应原性,间接免疫荧光、流式细胞术和激光共聚焦检测蛋白表达情况。试验选用14日龄雏鸡,各组免疫方式为口服+滴鼻。设立pLA-NDV-F/L. casei两次免疫组和三次免疫组、弱毒疫苗组、 pLA/L.casei、未攻毒PBS组和攻毒PBS组。间接ELISA方法检测雏鸡血清IgG、肠道、鼻腔、肺脏中sIgA抗体效价,评价试验组雏鸡攻毒保护率。结果表明,有94.10%的重组菌表达了F蛋白,且高效表达在干酪乳杆菌细胞表面,蛋白大小为62kDa,并能与抗NDV阳性血清特异性结合。各免疫组anti-F IgG和s Ig A抗体水平显著高于对照组,p LA-NDV-F/L. casei三次免疫组抗体持续时间比两次免疫组延长28 d,抗体峰值没有显著差异。免疫pLA-NDV-F/L. casei三次、两次、弱毒疫苗、pLA/L. casei和PBS的攻击保护率分别为80%、80%、90%、0%和0%。因此,利用干酪乳杆菌表达体系成功表达了携带部分抗原表位的NDVF基因,具备良好的反应原性和免疫原性,可诱导机体产生保护性免疫应答。     

传染性法氏囊病病毒VP4蛋白单克隆抗体的制备及鉴定

传染性法氏囊病病毒(IBDV)蛋白VP4在抑制宿主免疫应答中起重要作用,为制备IBDV VP4的单克隆抗体,以实验室保存的融合蛋白His-VP4免疫BALB/c小鼠,经过细胞融合、筛选、亚克隆后获得4株能稳定分泌抗VP4的单抗杂交瘤细胞株,分别命名为3B3、3H11、4C8和4G6,经间接ELISA测定4株单抗的亲和力解离常数分别为4.61×10–11、1.71×10–10、4.26×10–11和5.02×10–11,均为高亲和力抗体。4株单抗的重链类型分别为Ig G1、Ig G1、Ig G2b和Ig G1。进一步以Western blotting鉴定,该4株单抗均能特异地识别IBDV的VP4蛋白,间接免疫荧光和Western blotting试验表明4株单抗均能识别IBDV感染DF-1细胞后产生的VP4蛋白。该单抗为检测IBDV以及研究IBDV VP4的生物学作用奠定了基础。     

猪细小病毒VP2与大肠杆菌不耐热肠毒素B亚单位在干酪乳杆菌表面共表达

将分别编码猪细小病毒(PPV)主要免疫保护性抗原VP2蛋白与大肠杆菌不耐热肠毒素B亚单位(LTB)基因插入乳酸杆菌细胞表面表达载体pPG中, 成功构建了重组表达载体pPG-VP2-LTB, 将其电转化干酪乳杆菌Lactobacillus casei 393, 获得了表达猪细小病毒VP2-LTB融合蛋白的重组乳酸菌表达系统, 经2%乳糖诱导, SDS-PAGE和Western-blot检测表明, 有大小约78 kD的蛋白得到了表达, 具有与天然病毒蛋白一样的抗原特异性, 全细胞ELISA结果表明, LTB同     

鸡传染性法氏囊病病毒Gt株VP5基因缺失株感染性克隆的构建

传染性法氏囊病病毒 (IBDV)是双链,双节段RNA病毒,其基因组由A、B两个节段组成,编码结构蛋白VP1-VP4和非结构蛋白VP5。【目的】利用反向遗传操作构建拯救VP5基因缺失重组IBDV。【方法】利用体外定点突变技术,缺失IBDV Gt株VP5基因,通过多重PCR在基因组两端分别引入锤头状核酶序列(HamRz)和丁肝病毒核酶序列(HdvRz)。将带有核酶序列的IBDV基因组插入载体pCAGG的b肌动蛋白启动子下游,构建了IBDV感染性克隆pCAGGmGtA △VP5HRT,将该感染性克隆与pCAGGmGtBHRT共转染DFⅠ细胞。【结果】RT-PCR和间接免疫荧光均显示获得重组病毒,将其命名为rmGtA △VP5。IBDV VP5基因缺失感染性克隆的成功构建为从分子水平上深入研究vp5基因功能奠定了基础。     

表达传染性法氏囊病病毒(IBDV)VP2基因的重组马立克氏病病毒的构建

传染性法氏囊病（Infectious bursal disease,IBD）是一种由鸡传染性法氏囊病病毒（Infectious bursal disease virus,IBDV）引起的危害3～12周龄青年鸡的急性、高度接触性传染病.IBDV属于双RNA病毒科的禽双RNA病毒属,其基因组由A和B两个节段组成.研究表明,IBDV主要的抗原性及致病性位点均位于A片段,其中VP2蛋白具有血清型特异性位点,并能诱导产生抗病毒的血清中和抗体,是该病毒的主要抗原.     

Oral immunization with transgenic rice seeds expressing VP2 protein of infectious bursal disease virus induces protective immune responses in chickens

The expression of infectious bursal disease virus (IBDV) host-protective immunogen VP2 protein in rice seeds, its immunogenicity and protective capability in chickens were investigated. The VP2 cDNA of IBDV strain ZJ2000 was cloned downstream of the Gt1 promoter of the rice glutelin GluA-2 gene in the binary expression vector, pCambia1301-Gt1. Agrobacterium tumefaciens containing the recombinant vector was used to transform rice embryogenic calli, and 121 transgenic lines were obtained and grown to maturity in a greenhouse. The expression level of VP2 protein in transgenic rice seeds varied from 0.678% to 4.521% µg/mg of the total soluble seed protein. Specific pathogen-free chickens orally vaccinated with transgenic rice seeds expressing VP2 protein produced neutralizing antibodies against IBDV and were protected when challenged with a highly virulent IBDV strain, BC6/85. These results demonstrate that transgenic rice seeds expressing IBDV VP2 can be used as an effective, safe and inexpensive vaccine against IBDV.     

Expression of immunogenic VP2 protein of infectious bursal disease virus in Arabidopsis thaliana

VP2 protein is the major host-protective immunogen of infectious bursal disease virus (IBDV) of chickens. Transgenic lines of Arabidopsis thaliana expressing recombinant VP2 were developed. The VP2 gene of an IBDV antigenic variant E strain was isolated, amplified by RT-PCR and introduced into a plant expression vector, pE1857, having a strong promoter for plant expression. A resulting construct with a Bar gene cassette for bialaphos selection in plant (rpE-VP2) was introduced into Agrobacterium tumefaciens by electroporation. Agrobacterium containing the rpE-VP2 construct was used to transform Ar. thaliana and transgenic plants were selected using bialaphos. The presence of VP2 transgene in plants was confirmed by PCR and Southern blot analysis and its expression was confirmed by RT-PCR. Western blot analysis and antigen-capture ELISA assay using monoclonal anti-VP2 were used to determine the expression of VP2 protein in transgenic plants. The level of VP2 protein in the leaf extracts of selected transgenic plants varied from 0.5% to 4.8% of the total soluble protein. Recombinant VP2 protein produced in plants induced antibody response against IBDV in orally-fed chickens.     

Vaccination against very virulent infectious bursal disease virus using recombinant T4 bacteriophage displaying viral protein VP2

In order to develop a desirable inexpensive, effective and safe vaccine against the very virulent infectious bursal disease virus （vvIBDV）, we tried to take advantage of the emerging T4 bacteriophage surface protein display system. The major immunogen protein VP2 from the vvIBDV strain HK46 was fused to the nonessential T4 phage surface capsid protein, a small outer capsid （SOC） protein, resulting in the 49 kDa SOC-VP2 fusion protein, which was verified by sodium dodecylsulfate polyacrylamide gel electrophoresis and Western blot. Immunoelectromicroscopy showed that the recombinant VP2 protein was successfully displayed on the surface of the T4 phage. The recombinant VP2 protein is antigenic and showed reactivities to various monoclonal antibodies （mAbs） against IBDV, whereas the wild-type phage T4 could not react to any mAb. In addition, the recombinant VP2 protein is immunogenic and elicited specific antibodies in immunized specific pathogen free （SPF） chickens. More significantly, immunization of SPF chickens with the recombinant T4-VP2 phage protected them from infection by the vvIBDV strain HK46. When challenged with the vvIBDV strain HK46 at a dose of 100 of 50% lethaldose （LD50） per chicken 4 weeks after the booster was given, the group vaccinated with the T4-VP2 recombinant phage showed no clinical signs of disease or death, whereas the unvaccinated group and the group vaccinated with the wild-type T4 phage exhibited 100% clinical signs of disease and bursal damages, and 30%-40% mortality. Collectively, the data herein showed that the T4-displayed VP2 protein might be an inexpensive, effective and safe vaccine candidate against vvIBDV.     

含禽流感病毒M2e 氨基端抗原表位的重组传染性法氏囊病毒VP2 蛋白的免疫原性鉴定

【目的】构建传染性法氏囊病毒VP2蛋白展示禽流感M2e抗原表位的重组蛋白,研发预防H5或H9亚型禽流感和传染性法氏囊的基因工程疫苗。【方法】根据现有禽流感疫苗株M2e的氨基端12个氨基酸多肽序列(nM2e)序列,结合GenBank中H5和H9亚型禽流感病毒nM2e的比对结果,确定nM2e序列。用融合PCR分别将1拷贝H5或H9的nM2e序列插入IBD B87株VP2基因的PBC区,获得VP2BCnM2e重组基因。将重组基因克隆至杆状病毒表达系统,转染Sf9细胞进行表达。经间接免疫荧光和Western blotting检测Sf9细胞表达重组基因后,扩繁重组病毒,制备疫苗,间隔4周对非免鸡作2次重复免疫,用间接ELISA和鸡胚成纤维细胞中的病毒血清中和试验检测血清中VP2和nM2e的抗体效价。【结果】成功构建含H5或H9 nM2e的VP2BCnM2e重组基因,该重组基因在Sf9细胞中得到表达。经免疫鸡,两重组蛋白均能激发针对VP2和nM2e的抗体,VP2BCnM2eH5组抗体效价高于VP2BCnM2eH9组。【结论】两重组蛋白均具有免疫原性,VP2BCnM2eH5免疫原性更佳。     

MDV-1 VP22 conjugated VP2 enhancing immune response against infectious bursal disease virus by DNA vaccination in mice

VP22 of Marek’s disease virus serotype 1 (MDV-1) could function in protein transduction. In this study, an infectious bursal disease virus VP2 gene was fused to the carboxyl termini of VP22. It showed that the fusion protein did not spread into the bystander cells from the cells transfected with pVP22-VP2, as the VP22 alone could. The VP22 proteins were found to be translocated into all the nuclei in the neighboring COS-1 cells, as analyzed by a fluorescence assay. Although mice were immunized with the recombinant DNAs mixed with polyethylenimine (PEI) at a dose of 1:2, it failed to enhance the antibody response against IBDV VP2, as measured by the indirect ELISA assay, yet the cell mediated immune response was significantly increased. The ratio of CD8 /CD4 T cells was significantly increased in the immunized group with the fusion genes, compared with the group immunized with VP2 (P<0.05). Our results demonstrated that VP22 indeed enhances the cell-mediated response in the fused VP2 in a mice model system, possibly due to the fact that the IBDV VP2 could be carried into the surrounding cells at a limited level under pressure from MDV VP22.     

Synthesis of reassortant infectious bursal disease virus in chickens injected directly with infectious clones from different virus strains

The infectious bursal disease virus (IBDV), a member of the Birnaviridae family, containing a bisegmented double-stranded RNA genome, encodes four structural viral proteins, VP1, VP2, VP3, and VP4, as well as a non-structural protein, VP5. In the present paper, the segment A from two IBDV strains,field isolate ZJ2000 and attenuated strain HZ2, were inserted into one NaeⅠ site by site-directed silent mutagenesis and subcloned into the eukaryotic expression plasmid pCI under the control of the human cytomegalovirus (hCMV) immediate early enhancer and promoter to construct the recombinant plasmids pCI-AKZJ2000 and pCI-AKHZ2, respectively. Each of the two recombinants was combined with another recombinant pCI plasmid containing the marked segment B of strain HZ2 (pCI-mB), and injected intramuscularly into nonimmunized chickens. Two chimeric IBDV strains were recovered from the chickens. Two out of eight chickens in each of two groups showed the bursal histopathological change. The reassortant virus derived from pCI-AKZJ2000/pCI-mB can infect chicken embryos and shows relatively low virulence. We have developed a novel virus reverse genetic approach for the study of IBDV. The results also form the basis for investigating the role of VP1 in viral replication and pathogenecity.     

Characterization of tubule and monomer derived from VP4 protein of infectious bursal disease virus

The VP4 protein of infectious bursal disease virus (IBDV) is a serine protease that processes the polyprotein for viral assembly. VP4 has been found to associate primarily with type II IBDV tubules that are 24 nm in diameter. In this study, a chimeric VP4, assigned as HS1VP4, was constructed with a VP4-autocleavage site inserted between the N-terminal His-tag and the VP4 sequence. The results showed that the VP4 forms tubules after the self-cleavage of HS1VP4 when expressed in Escherichia coli. Furthermore, a deletion of 28 amino acids at the C-terminus of VP4 resulted in monomers and dimers instead of tubule formation; mutants of S652A and K692A at active site destroyed the activity. The endopeptidase activity of these monomers and dimers was approximately 12.5 times higher than that of VP4 tubules. Additionally, the formation of tubules inhibited VP4 protease activity, as demonstrated through in vitro assays. The production and characterization of monomers or dimers that have greater endopeptidase activity and protease activity than tubules can provide further insight into VP4 tubule assembly and the regulation of VP4 activity in host cells; this insight will facilitate the development of new anti-IBDV strategies.     

Exchange of the VP5 of infectious bursal disease virus in a serotype I strain with that of a serotype II strain reduced the viral replication and cytotoxicity

Infectious bursal disease virus (IBDV), belonging to Avibirnavirus genus in the Birnaviridae family, consists of two segments of double-strand RNA. There are two distinct serotypes of IBDV, the pathogenic serotype I and the non-pathogenic serotype II. Comparison of the deduced amino acid sequences of a panel of VP5 genes retrieved from GenBank revealed a high identity among strains within the serotype I or serotype II group but a low identity between strains across two serotypes. In this study, we rescued two mosaic viruses, rGtGxVP5 and rGt2382VP5 by exchanging the VP5 gene of a cell culture-adapted serotype I Gt strain with its counterpart of the very virulent IBDV Gx strain, or a non-pathogenic 23/82 strain of the serotype II. In comparison to the parental strain rGt virus, the rGtGxVP5 showed the similar viral replication, cytotoxicity and the ability of inducing apoptosis; however, the other mosaic virus rGt2382VP5 had a lower titer and a reduced cytotoxicity. Although exchange of VP5 within serotype I group did not alter the viral replication and cytotoxicity of Gt strain, exchange of VP5 in the serotype I with that of a serotype II reduced the viral replication and cytotoxicity on chicken embryo fibroblast (CEF) cells. Therefore, the VP5 of serotype II may be one of the factors responsible for the distinct pathogenic features of two serotypes.     

重组禽腺联病毒介导的miRNA抑制传染性法氏囊病病毒在鸡胚内的复制

【目的】在鸡胚水平上探索VP1和VP2基因特异miRNA抑制传染性法氏囊病病毒(infectious bursaldisease virus,IBDV)复制的可行性。【方法与结果】将表达VP1基因特异miRNA重组载体pAITR-RFPmiVP1或VP2基因特异miRNA重组载体pAITR-RFPmiVP2E与禽腺联病毒(avian adeno-associated virus,AAAV)包装载体pcDNA-ARC和腺病毒辅助载体pHelper共转染AAV-293细胞,获得重组病毒rAAAV-RFPmiVP1和rAAAV-RFPmiVP2E,用同样方法获得不表达miRNA的rAAAV-RFP和表达对照miRNA的rAAAV-RFPmiVP2con。电镜观察显示重组病毒具有典型的AAAV颗粒形态;PCR检测结果表明其基因组中含miRNA表达盒;经poly(A)加尾RT-PCR检测证明重组病毒感染细胞能表达基因特异的miRNA。分别将重组病毒经卵黄囊途径接种8日龄SPF鸡胚,然后经绒毛尿囊膜途径用Lukert株IBDV攻毒,收获鸡胚进行IBDV组织细胞半数感染剂量(TCID50)测定。结果在攻毒后第3天,rAAAV-RFP和rAAAV-RFPmiVP2con接种组的IBDV TCID50为8.0 log10,rAAAV-RFPmiVP1和rAAAV-RFPmiVP2E接种组的IBDV TCID50分别下降到1.0和1.5 log10;在攻毒后第6天,rAAAV-RFP和rAAAV-RFPmiVP2con接种组的IBDV TCID50仍为8.0 log10,rAAAV-RFPmiVP1和rAAAV-RFPmiVP2E接种组的TCID50分别下降到0.8和2.0 log10。【结论】rAAAV是有效的miRNA鸡胚导入载体,表达的VP1和VP2基因特异miRNA能有效阻断IBDV复制。